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CC BY-NC-ND license (http://creativeBackground/Purpose: Fontan operation has evolved from atriopulmonary connection to total
cavopulmonary connection (TCPC) due to its advantages in terms of hemodynamics and reduc-
tion of atrium-related complications. We analyzed the early and intermediate-term results of
extracardiac conduit TCPC (EC-TCPC) procedure in patients with functional single ventricle to
investigate the risk factors of surgical mortality and intermediate failure.
Methods: Retrospective review of the medical records of 88 consecutive patients with func-
tional single ventricle who underwent EC-TCPC from 2000 to 2013 was conducted.
Results: The follow-up was 100% complete, ranging from 3 months to 13 years (mean
7.0  3.8 years). There were two (2.3%) hospital and 18 (20.4%) late deaths. The estimated
event-free survival rates at 1 year, 5 years, and 10 years were 90.6%, 89.3%, and 77.2%, respec-
tively. On univariate analysis, fenestration was the only risk factor for surgical mortality
(p Z 0.027). On multivariate analysis, the significant atrioventricular valve regurgitation
was the only risk factor for intermediate failure (p Z 0.017).
Conclusion: The clinical results of EC-TCPC in patients with functional single ventricle were
satisfactory. The patients who needed fenestration during operation had higher risk of surgicalhave no conflicts of interest relevant to this article.
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Diagnosis
Heterotaxy, double-outlet right ve
CAVSD
Tricuspid atresia
Double-inlet single ventricle
Pulmonary atresia with intact ven
septum
Mitral atresia
Ebstein anomaly
CAVSD
Hypoplastic left heart syndrome
L-Transposition of great arteries
Total
CAVSD Z complete atrioventricularmortality. Significant atrioventricular valve regurgitation had negative impact on intermediate
survival.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Fontan-type operation has been performed in a wide vari-
ety of functional single-ventricle hearts.1e3 This procedure
has evolved from atriopulmonary connection to total cav-
opulmonary connection (TCPC) with either an intracardiac
lateral tunnel (LT) or the extracardiac conduit (EC) tech-
nique due to its advantages in terms of hemodynamics and
reduction of atrium-related complications.4e8
In recent times, the EC type of reconstruction has
become more popular than the LT type due to the following
reasons: easier technique; suitable for all kinds of single-
ventricle patients, especially those with heterotaxy syn-
drome with anomalous systemic or pulmonary venous re-
turn; avoidance of systemic cooling and cardioplegic arrest;
and extensive atrial manipulation, all of which may have a
negative effect on survival.9 However, there are still some
unsolved issues regarding the use of EC-TCPC, including
absence of growth potential, the most optimal size, risk of
thromboembolism, and the significance of fenestration. In
this study, we retrospectively analyzed our early and
intermediate-term results during the 13-year period in 88
consecutive patients with functional single-ventricle pa-
thology to investigate the risk factors of surgical mortality
and intermediate failure following EC-TCPC.Methods
Patient selection
A single-center retrospective analysis of 88 consecutive
patients who underwent EC-TCPC for various functionalients.
N (%)
ntricle, 37 (42.0)
18 (20.5)
11 (12.5)
tricular 7 (8.0)
4 (4.5)
4 (4.5)
3 (3.4)
2 (2.3)
2 (2.3)
88 (100.0)
septal defect.single-ventricle hearts from 2000 to 2013 was conducted
(Table 1). This study was approved by the Institutional
Review Board of Kaohsiung Veterans General Hospital and
the need for written informed consent from the patients
was waived.
The study cohort included 48 (54.5%) male and 40
(45.5%) female patients. The mean age at operation was
6.3  5.3 years (range 1.5e33 years) and the mean body
weight at operation was 20.9  13.3 kg (range 9.2e70 kg).
Exclusion of patients with failed palliation
Three patients with right atrial isomerism, total anomalous
pulmonary venous connection, and pulmonary venous
obstruction who failed to survive the initial palliation were
not included in this study.
Operative characteristics
Although the use of noninvasive computed tomography
might reduce the use of diagnostic cardiac catheterization,
two-dimensional echocardiography and complete cardiac
catheterization were performed in all patients before the
operation.10 The indications for EC-TCPC in our institute
are as follows: aged over 1 year, body weight of more than
9 kg, mean pulmonary artery pressure of less than
20 mmHg, ejection fraction of more than 30%, and Nakata
index of more than 150 mm2/m2. Primary EC-TCPC was
performed in only three patients and 85 patients had
received various kinds of palliative procedures before the
completion of EC-TCPC. On average, 2.2 palliative pro-
cedures were performed for each patient before EC-TCPC
completion (Table 2). The bidirectional Glenn shunt wasTable 2 Previous procedures.
Procedure n
Bidirectional Glenn shunt 85
Systemic pulmonary arterial shunt 47
Pulmonary artery banding 16
Pulmonary artery angioplasty 12
Atrial septectomy 10
DamuseKayeeStansel procedure 3
Repair coarctation 3
Atrioventricular valve repair 2
Bulboventricular resection 1
Atrioventricular valve replacement 1
Pulmonary vein angioplasty 1
Atriopulmonary anastomosis 1
Total (average procedure/patient) 182 (2.2)
320 J.-Y. Pan et al.performed at the mean age of 2.9  3.1 years, and the EC-
TCPC was completed at the mean age of 6.0  4.5 years.
The mean procedural interval between the bidirectional
Glenn shunt and EC-TCPC completion was 3.1  5.2 years.
More-than-moderate degree (3þ) of atrioventricular valve
regurgitation was identified in 12 patients and valve repair,
whenever feasible, was performed on five of these 12
patients.
Surgical technique
The operation was performed through the median ster-
notomy using standard cardiopulmonary bypass. The supe-
rior vena cava was cannulated just proximal to the
innominate vein and the inferior vena cava was cannulated
just above the cavophrenic junction. Normothermic or mild
hypothermic cardiopulmonary bypass was instituted
initially. If an intracardiac procedure such as atrioventric-
ular valve repair, atrial septectomy, or resection of sub-
aortic conus was required, cold crystalloid cardioplegic
arrest was used for myocardial protection. The inferior
vena cava was transected at the atriocaval junction and a
polytetrafluoroethylene (PTFE) straight tube graft (Gore-
Tex Stretch Vascular Graft, W.L. Gore & Associates, Flag-
staff, AZ, USA) was interposed between the inferior vena
cava and the right pulmonary artery in all patients except in
a 33-year-old patient with a 26-mm Dacron graft. The size
of the graft was 16 mm in six patients, 18 mm in 24 pa-
tients, 20 mm in 35 patients, and 22 mm in 22 patients
(Figure 1).
A fenestration was created by interposition of the PTFE
graft (diameter ranged from 4 mm to 7 mm) between EC
and atrium in 15 (17.1%) patients with low cardiac output
after TCPC completion. The size of the fenestration was
further adjusted by stepwise clipping of the graft with
hemoclip to achieve the most balanced hemodynamic and
systemic oxygen saturation.
Follow-up
Follow-up was 100% complete and the period ranged from
3 months to 13 years (mean 7.0  3.8 years). Surgical
mortality was defined as any death within 30 days afterFigure 1 Distribution of the size of the extracardiac conduit.
e-PTFE Z expanded polytetrafluoroethylene.surgery or after 30 days but during the same hospitalization
period subsequent to the operation.
Two kinds of antiplatelet drugs (aspirin and dipyr-
idamole) were prescribed for all patients to circumvent
thromboembolic complication postoperatively. Further-
more, warfarin was added initially in eight patients with
atrial fibrillation (N Z 7) or after a mechanical valve
replacement (NZ 1). The warfarin dose was titrated to the
international normalization ratio of 2.0e3.0.
Chest roentgenogram, standard 12-lead electrocardio-
gram, and two-dimensional echocardiography were per-
formed every 6 months. Cardiac catheterization had been
performed in 51 patients 1 year postoperatively for evalu-
ating the postoperative pulmonary arterial pressure and
pulmonary vascular resistance change.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences for Windows software sys-
tem, version 17.0 (SPSS Inc., Chicago, IL, USA). Continuous
variables acquired from the clinical characteristics were
expressed as mean  standard deviation and were
compared using the independent t test. The Chi-square test
or Fisher exact test according to the number of events for
variables appraised was used for comparisons made be-
tween categorical variables. Actuarial survival and cardiac-
related event-free survival were estimated by the
KaplaneMeier method with the log-rank test. Cox propor-
tional hazard analysis was used for identifying the signifi-
cant risk factor for the intermediate failure. A two-tailed p
value of less than 0.05 was considered statistically
significant.
Results
Operative characteristics
Forty-five patients (51.1%) underwent EC-TCPC at the age
of more than 4 years. Twenty-one patients (23.9%) under-
went 26 concomitant procedures during EC-TCPC comple-
tion (Table 3). The cardiopulmonary bypass time ranged
from 48 minutes to 442 minutes (mean
125.6  89.7 minutes). The cardioplegic cardiac arrest was
used in 15 patients in whom the cardiac ischemic timeTable 3 Concomitant procedures.
Procedure n
Pulmonary artery angioplasty 8
Atrioventricular valve repair 5
Atrial septectomy 4
Right ventricular exclusion 4
Permanent pacer implantation 2
DamuseKayeeStansel procedure 1
Resection of subaortic conus 1
Takedown of previous atriopulmonary
anastomosis
1
Total procedure number (patient) 26 (21)
Table 4 Analyzed predictors for surgical mortality
(N Z 2).
No
n/N, %
Yes
n/N, %
p
Demographics
Age  4 y 1/43, 2.3 1/45, 2.2 >0.99
Male 1/48, 2.1 1/40, 2.5 >0.99
Pre-PAP  15 mmHg 1/64, 1.6 1/24, 4.2 0.473
Pre-PVR  2.5 WU$m2 1/73, 1.4 1/15, 6.7 0.313
Pathology
Asplenia 2/80, 2.5 0/8, 0 >0.99
AVVR  3þ 2/76, 2.6 0/12, 0 >0.99
CAVV 2/52, 3.8 0/37, 0 0.511
Dextrocardia 1/66, 1.5 1/22, 4.5 0.440
Heterotaxy 2/51, 3.9 0/37, 0 0.507
RV morphology 2/40, 5.0 0/48, 0 0.204
None-situs solitus 2/62, 3.2 0/26, 0 >0.99
SVDA 2/58, 3.4 0/30, 0 0.545
TAPVC 2/86, 2.3 0/2, 0 >0.99
Previous palliation
Atrial septectomy 2/78, 2.6 0/10, 0 >0.99
BDG 0/3, 0 2/85, 2.4 >0.99
PA angioplasty 2/76, 2.6 0/12, 0 >0.99
PA banding 2/72, 2.8 0/16, 0 >0.99
Shunt 2/41, 4.9 0/47, 0 0.214
Operative variables
Aortic clamp 1/73, 1.4 1/15, 6.7 0.313
CPB  2 h 1/59, 1.7 1/29, 3.4 >0.99
Fenestration 0/73, 0 2/15, 13.3 0.027
Postoperative course
PLE  2 wk 2/48, 4.2 0/40, 0 >0.99
Post-PAP  15 mmHg 0/39, 0 2/49, 4.1 0.501
SV arrhythmia 2/81, 2.5 0/7, 0 >0.99
AVVR Z atrioventricular valve regurgitation;
BDG Z bidirectional Glenn; CAVV Z common atrioventricular
valve; CPBZ cardiopulmonary bypass; PAZ pulmonary artery;
PLE Z pleural effusion; post-PAP Z postoperative pulmonary
arterial pressure; pre-PAP Z preoperative pulmonary arterial
pressure; pre-PVR Z preoperative pulmonary vascular resis-
tance; RV Z right ventricle; SV Z supraventricular;
SVDA Z systemic venous drainage anomaly; TAPVC Z total
anomalous pulmonary venous connection; WU Z Wood units.
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49.4  27.5 minutes). Atrioventricular valve repair for
regurgitation (>3þ) was performed in five of the 12
patients.
Outcomes
The endotracheal tube was extubated within 24 hours in 77
patients (87.5%). Prolonged pleural effusion for more than
14 days occurred in 40 patients (45.5%). The mean pulmo-
nary artery pressure was 12.7  4.0 mmHg before EC-TCPC
and 15.9  2.5 mmHg after EC-TCPC; the preoperative
pulmonary vascular resistance was 2.11  0.79 WU$m2; the
arterial oxygen saturation was 84.2%  6.4% before EC-
TCPC and 96.9%  2.6% after EC-TCPC; the ventricular
end-diastolic pressure was 8.7  4.2 mmHg before EC-TCPC
and 7.5  2.8 mmHg after EC-TCPC; the pulmonary-to-
systemic flow ratio was 0.9  0.2 before EC-TCPC and
1.0  0.2 after EC-TCPC. There were two surgical mortal-
ities. A 28-month-old boy with dextrocardia, tricuspid
atresia, and transposition of great arteries developed re-
fractory supraventricular tachyarrhythmia. He died of
multiple organ failure 4 days after the operation. The other
one was a 6-year-old girl with Ebstein anomaly, who
developed severe low cardiac output after the operation.
After 7-day extracorporeal membranous oxygenation, she
died of multiple organ failure.
Late death occurred in 13 patients. The causes of death
were ventricular dysfunction in four patients, pneumonia
with sepsis in three patients, protein-losing enteropathy
associated with congestive heart failure in two patients,
conduit thrombosis due to high pulmonary vascular resis-
tance in two patients, pulmonary arteriovenous malfor-
mation in one patient, and nephrotic syndrome in one
patient. One patient underwent heart transplantation for
intractable heart failure 1 year after EC-TCPC. On Cox
proportional hazard analysis, more-than-moderate atrio-
ventricular valve regurgitation was the only risk factor for
intermediate death (p Z 0.017).
Fenestration
In total, 15 patients (17.1%) required fenestration and four
of them (4.6%) were fenestrated under the subsequent
rescue condition in the intensive care unit due to low car-
diac output. Eventually, two of these 15 patients (1 out of
the 4 rescued patients) died of multiple organ failure. All
the residual fenestrations (n Z 13) were noted to be
occluded spontaneously during the follow-up cardiac
catheterization 1 year after the operation. On univariate
analysis, fenestration was the only risk factor for surgical
mortality (p Z 0.027; Table 4).
Arrhythmia
Two patients developed complete atrioventricular block
before operation and a permanent pacemaker was
implanted during EC-TCPC. Seven patients developed atrial
fibrillation before operation due to high atrial pressure and
this was resolved in four patients after EC-TCPC. Medicalrate control with anticoagulation therapy was appropriate
in the three residual patients.Reoperation
Seven patients (8.0%) were reoperated and five of them
died during the follow-up period. Atrioventricular valve
operations were performed in four patients (3 re-
placements and 1 repair) because of the deteriorated
atrioventricular valve regurgitation with ventricular failure.
Three of them died and one patient received heart trans-
plantation at last. The DamuseKayeeStansel procedure
was performed in one patient for the progressive subaortic
stenosis, but this patient eventually died of protein-losing
enteropathy. An EC-TCPC was taken down in one patient
due to ventricular failure and conduit thrombosis, and this
322 J.-Y. Pan et al.patient finally died. The hemiazygos to left pulmonary
arterial anastomosis was performed in one patient for
progressive cyanosis and satisfactory result was achieved.
The estimated event-free survival rates at 1 year, 5 years,
and 10 years were 90.6%, 89.3%, and 77.2%, respectively
(Figure 2).Discussion
EC-TCPC
In Taiwan, severe congenital heart diseases account for
11.5% of all cases. Among them, the single-ventricle heart
accounts for 0.6% of all cases. The estimated survival at
5 years of age is 66.0% in this population.11 Significant im-
provements of outcomes after Fontan operation for this
group of patients have evolved since the original descrip-
tion of the procedure by Fontan and Baudet in 1971.1 The
factors improving early survival include better under-
standing of Fontan physiology, careful selection and prep-
aration of candidate, earlier and staging operation, and
refinement in procedure. LT-type TCPC and EC-TCPC are
the two most common modifications of the Fontan opera-
tion with comparable operative survival and midterm re-
sults. However, EC-TCPC has the advantages of
applicability to almost all kinds of complex cardiac anom-
alies, especially for patients with heterotaxy and abnormal
systemic or pulmonary venous return; less cardiac arrest
and cardiopulmonary bypass times; avoidance of atriotomy
and suture line loading in atrium; more efficient laminarFigure 2 KaplaneMeier curve demonstrated the estimated
event-free survival rates at 1 year, 5 years, and 10 years to be
90.6%, 89.3%, and 77.2%, respectively.flow with less energy loss; and fewer postoperative
dysrhythmias.7,9,12,13
Although the artificial conduit used for the EC-TCPC
technique has been reported to limit growth potential,
recent reports have demonstrated that longitudinal growth
of the autologous vessels above and below the conduit can
compensate this limitation.14,15
Conduit size
In our early series, one of six patients with 16-mm EC
experienced conduit thrombosis 6 months after EC-TCPC
despite dual-antiplatelet therapy and eventually, revision
for the EC replacement was mandatory. Theoretically, the
smaller size of EC might be less relevant to the thrombotic
episode and the elevated pulmonary vascular resistance in
this particular patient might play an important role in flow
stasis, and then in subsequent EC thrombosis.16 Therefore,
considering the general adult inferior vena cava diameter
of around 20 mm, consistent with the previous report, the
PTFE with diameter of 18e22 mm was used as the EC size of
choice for patients with body weight of more than 10 kg.8,16
Fenestration
The effect of fenestration is still controversial. In most
contemporary literatures, the fenestration was used
routinely; additionally, it was advocated that fenestration
would not affect early survival, resource use, or pleural
drainage amount.7,17e19 In this study, however, we per-
formed fenestration selectively in high-risk patients with
elevated pulmonary vascular resistance (>2.5 WU$m2).20
This strategy might bias the fenestration as the only risk
factor for surgical mortality on univariate analysis. From
our limited experiences, we felt that fenestration was a
valuable adjunctive procedure without significant draw-
back and might be beneficial for the high-risk patients
during the perioperative period.
Antithrombotic issue
Routine and lifelong anticoagulation therapy was advo-
cated to prevent the thrombosis and late stenosis of EC.8,21
Without anticoagulation therapy, 20e23% of thrombus for-
mation in the EC was also reported.22,23 However, the
optimal anticoagulation level for a patient after EC-TCPC is
still unknown.24,25 We reserved the anticoagulant therapy
for those with mechanical valve or supraventricular ar-
rhythmias to avoid major bleeding complication. Instead,
dual-antiplatelet therapy with aspirin and dipyridamole
was used for all other patients. During the mean follow-up
of 7.0  3.8 years, EC thrombosis was noted in two patients
(2.3%). Further study is necessary to confirm the role of
anticoagulation and antiplatelet therapies in ameliorating
the EC thrombosis.
Outcomes and reoperation
The surgical mortality regarding Fontan-type operations
declined dramatically to less than 5% during the past two
decades and this rate in our series was 2.3%, which was
Extracardiac conduit TCPC 323fairly comparable to the published results.7,13,19 The
reoperation rate of Fontan population after 5e15 years’
follow-up was reported to be 29%.2 In this study, the
reoperation rate was 8% (7/88). Four of the seven reoper-
ations were mandatory for the intractable ventricular fail-
ure associated with significant atrioventricular valve
regurgitation and the results were unsatisfactory. This fact
made the significant atrioventricular valve regurgitation
the only risk factor for intermediate failure on multivariate
analysis. Heart transplantation was advocated as another
therapeutic option for this difficult population.26 However,
donor heart shortage, especially in this age group, is an
unsolved global issue. We only had a single transplantation
experience for failing Fontan.
Risk analysis
On univariate analysis, fenestration was the only risk factor
for surgical mortality (p Z 0.027). Significant atrioventric-
ular valve regurgitation was the only risk factor for inter-
mediate failure. Driscoll and colleagues2 also demonstrated
the same result. Early operation and more aggressive
management of atrioventricular valve regurgitation might
be mandatory for salvaging this critical population.
Limitation of the study
The natures of retrospective, nonrandomized, and small
population are the inevitable weakness of this study. A
larger, prospective, and randomized multicenter coopera-
tive study will certainly circumvent this predicament.
Conclusion
In conclusion, we demonstrated 88 consecutive patients
with functional single ventricle who underwent EC-TCPC
with satisfactory long-term clinical outcomes. The patients
who needed fenestration during operation had higher risk
of surgical mortality. Significant preoperative atrioventric-
ular valve regurgitation had negative impact on interme-
diate survival.References
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